Medicine details

ImageCesalin-10
NameCesalin-10
DosageInjection
Generic NameCisplatin
Classes Anticancer/Antineoplastic Agent
Alkylating Agent
Diseases Bladder Cancer
Cancer
Ovarian Cancer
Testicular Cancer
CompanyTechno Drugs Ltd.

Drug Package Details

Strength10 mg/ml
Storage Condition
Origin CountryBangladesh
Commercial Pack1
Price per pack220.00
Cost per pack193.60
Package unit10 mg vial
Price per unit220.00
Cost per unit193.60
Discount0
Coupon
Remarks

Cisplatin

Cisplatin is an anti neoplastic drug. The binding of cisplatin to genomic DNA in the cell nucleus to create interstrand and intrastrand cross-links is the primary mechanism of the cytotoxic activity. This causes disruptions in the regular transcription and/or DNA replication processes, which sets off cytotoxic reactions that result in cell death.

Cisplatin injection is indicated for the treatment of:

  • Advanced testicular cancer
  • Advanced ovarian cancer
  • Advanced bladder cancer
  • Hydration and Anti-Emetic Treatment: Patients receiving cisplatin for injection must be adequately hydrated prior to treatment. Maintain adequate hydration and urinary output for 24 hours after receiving cisplatin for injection. As needed, administer antiemetics before and after treatment.
  • Advanced Testicular Cancer: Cisplatin injection has been given intravenously every day for 5 days per cycle at a dose of 20 mg/m2. Other doses and combination regimens have been used.
  • Advanced Ovarian Cancer: Cisplatin injection has been given intravenously once every 3 to 4 weeks on Day 1 at a dose of 75 mg/m2
  • to 100 mg/m2. Other doses and combination regimens have been used.
  • Advanced Bladder Cancer: Cisplatin for injection has been administered at 50 mg/m2 to 70 mg/m2 intravenously per cycle once every 3 to 4 weeks. For heavily pretreated patients, an initial dose of 50 mg/m2 per cycle repeated every 4 weeks is recommended. Other doses and combination in regimens have been used. 
  • Consider alternative treatments or dose reductions for patients with impaired creatinine clearance, myelosuppression, or neuropathy. Consider permanent discontinuation for Grade 3-4 neuropathy.

Common adverse reactions are-

  • nephrotoxicity
  • peripheral neuropathy
  • nausea and vomiting
  • myelosuppression
  • ototoxicity
  • Nephrotoxicity: Injection cisplatin can cause severe renal toxicity, including acute renal failure. Maintain adequate hydration. In patients with renal impairment, consider dose reductions or alternative treatments.
  • Peripheral Neuropathy: Cisplatin injection may result in dose-related peripheral neuropathy.
  • Nausea and Vomiting: Cisplatin can cause severe nausea and vomiting. Antiemetics should be taken beforehand.
  • Myelosuppression: Cisplatin for injection can cause severe myelosuppression, with infections leading to death. Monitor blood counts and stop therapy as needed.
  • Cisplatin injection can result in severe hypersensitivity reactions such as anaphylaxis and death. Facial edema, wheezing, tachycardia, and hypotension have all been reported as symptoms. Patients who had previously been exposed to cisplatin for injection experienced hypersensitivity reactions within minutes of administration.
  • Cisplatin for injection can cause ototoxicity, which can be severe and cumulative. Take into account audiometric and vestibular function monitoring.
  • Patients receiving standard recommended doses of cisplatin for injection have experienced optic neuritis, papilledema, and cortical blindness. Blurred vision and altered color perception have been reported following the use of cisplatin injection regimens with higher doses and dose frequencies.
  • The use of cisplatin for injection has been linked to the development of acute leukemia. Cisplatin for injection was generally given in combination with other leukemogenic agents in these reports.
  • According to human data, when administered to a pregnant woman, cisplatin for injection can cause fetal harm. Inform pregnant women and females of reproductive potential about the risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 14 months after the last dose of cisplatin for injection. Advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 11 months after the last dose of cisplatin for injection
  • During the administration of cisplatin for injection, injection site reactions can occur. Local soft tissue toxicity has been reported following cisplatin injection extravasation. The severity of local tissue toxicity appears to be proportional to the concentration of cisplatin in the injection solution. Infusion of solutions containing more than 0.5 mg/mL cisplatin for injection may cause tissue cellulitis, fibrosis, necrosis, pain, edema, and erythema. Because of the risk of extravasation, keep a close eye on the infusion site during drug administration.

Contraindication

Contraindicated in patients with severe hypersensitivity to cisplatin.

Contraindicated in severe renal impairment.